secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001493152-25-011082
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment
--------------------------------------------------------------------------------

- Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.
- Revenues increased to $7.8M from $7.3M, driven by a contract modification with Cipla.
- Cash and equivalents $9.5M; sufficient to fund operations through anticipated Merger close in H1 2025.
- Proposed merger with Cullgen expected to close H1 2025; plans to divest Phase 2-ready PUR3100 and iSPERSE technology.
- PUR1900 Phase 2b enrollment paused; no further financial responsibility; 2% royalties on future net sales outside U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315225011082/0001493152-25-011082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315225011082/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer